(XLO) – StreetInsider.com Reports
-
Xilio Therapeutics (XLO) Announces $11.3 Million Private Placement Equity Financing, License Agreement with Gilead (GILD)
-
Gilead Sciences (GILD) and Xilio (XLO) Enter Exclusive License Agreement for Tumor-Activated IL-12 Program
-
Xilio Therapeutics (XLO) Halted, News Pending
-
Xilio Therapeutics (XLO) Receives Nasdaq Non-compliance Notice
-
Xilio Therapeutics (XLO) Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301
-
Xilio Therapeutics (XLO) Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
-
Xilio Therapeutics (XLO) Announces Departure of Martin Huber, Appoints René Russo as Next President
-
Xilio Therapeutics (XLO) Promotes Katarina Luptakova to Chief Medical Officer, Scott Coleman to Chief Development Officer
-
Xilio Therapeutics (XLO) Appoints Chris Frankenfield as COO
-
Xilio Therapeutics (XLO) Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
-
Xilio Therapeutics Inc (XLO) PT Lowered to $10 at Morgan Stanley
-
Xilio Therapeutics Inc (XLO) PT Lowered to $9 at Guggenheim
-
Chardan Capital Markets Starts Xilio Therapeutics Inc (XLO) at Buy
-
Xilio Therapeutics Inc (XLO) PT Lowered to $15 at Guggenheim
-
Xilio Therapeutics (XLO) Files $250M Mixed Shelf
-
Xilio Therapeutics (XLO) Files $250M Mixed Shelf
-
Xilio Therapeutics (XLO) Announces Pipeline and Business Updates, Reports Q3
-
Xilio Therapeutics (XLO) Appoints Tomas J. Heyman to its Board
-
Xilio Therapeutics (XLO) Reports Positive Prelim Phase 1 Dose-Escalation Data for XTX101
-
Xilio Therapeutics (XLO) Announces CFO Resignation
-
Xilio Therapeutics (XLO) Announces Promotion of Martin Huber, M.D., to President
-
Xilio Therapeutics Inc (XLO) PT Lowered to $25 at Guggenheim
-
Xilio Therapeutics (XLO) Reports Pipeline and Business Highlights
-
Xilio Therapeutics (XLO) Commences Patient Dosing in Phase 1/2 Clinical Trial of XTX202
-
UPDATE: H.C. Wainwright Starts Xilio Therapeutics Inc (XLO) at Buy
-
Xilio Therapeutics (XLO) Appoints Yuan Xu to its Board
-
Xilio Therapeutics (XLO) Announces Pipeline Updates, Reports Q3 Reults
-
Guggenheim Starts Xilio Therapeutics Inc (XLO) at Buy
-
UPDATE: Morgan Stanley Starts Xilio Therapeutics Inc (XLO) at Overweight Expecting Meaningful Improvement to IO Treatment
-
UPDATE: Raymond James Starts Xilio Therapeutics Inc (XLO) at Outperform
-
UPDATE: Cowen Starts Xilio Therapeutics Inc (XLO) at Outperform
-
Xilio Therapeutics (XLO) Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at SITC
-
Xilio Therapeutics (XLO) IPO Opens 6% Lower After Pricing at Low End of Range
-
Xilio Therapeutics (XLO) Announces 7.35M Share IPO at $16-$18/sh
-
Xilio Therapeutics (XLO) Files For Up to $100M IPO
Back to XLO Stock Lookup